Menopause Spray Brings 3Q Profit
Vivus Starts Phase III Effort With Obesity Combo Qnexa
By Randall Osborne
Monday, November 12, 2007
Riding on third-quarter profits that surprised some analysts thanks to the sale of its spray drug for menopause symptoms earlier this year, Vivus Inc. began the first of two pivotal Phase III trials with Qnexa, the combination phentermine/topiramate drug dosed once daily for obesity. (BioWorld Today)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.